Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting
April 11, 2024 07:30 ET
|
Dianthus Therapeutics, Inc.
NEW YORK and WALTHAM, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of...
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 05, 2024 16:30 ET
|
Dianthus Therapeutics, Inc.
NEW YORK and WALTHAM, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (“Dianthus”), a clinical-stage biotechnology company dedicated to advancing the next generation of...
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results
March 21, 2024 16:01 ET
|
Dianthus Therapeutics, Inc.
Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) initiated in Q1’24 with top-line results anticipated in 2H’25 $389 million of pro forma cash, including $216 million of net proceeds from a...
Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 07, 2024 16:30 ET
|
Dianthus Therapeutics, Inc.
NEW YORK and and WALTHAM, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus”), a clinical-stage biotechnology company dedicated to advancing the next...
Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG)
February 26, 2024 07:00 ET
|
Dianthus Therapeutics, Inc.
Top-line results from gMG MaGic trial anticipated in 2H 2025 Building a neuromuscular franchise with DNTH103 through additional planned Phase 2 trials in Multifocal Motor Neuropathy (MMN) and Chronic...
Dianthus Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
February 23, 2024 08:00 ET
|
Dianthus Therapeutics, Inc.
NEW YORK and WALTHAM, Mass., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of...
Dianthus Therapeutics to Participate at the Guggenheim 6th Annual Biotechnology Conference
January 31, 2024 16:05 ET
|
Dianthus Therapeutics, Inc.
NEW YORK and WALTHAM, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of...
Dianthus Therapeutics Announces $230 Million Private Placement
January 22, 2024 07:30 ET
|
Dianthus Therapeutics, Inc.
NEW YORK and WALTHAM, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (“Dianthus” or the “Company”) (NASDAQ: DNTH), a clinical-stage biotechnology company dedicated to advancing...
Dianthus Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024 08:30 ET
|
Dianthus Therapeutics, Inc.
NEW YORK and WALTHAM, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of...
Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 04, 2023 16:09 ET
|
Dianthus Therapeutics, Inc.
NEW YORK and WALTHAM, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (“Dianthus”), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody...